Compare Gilead Sciences, Inc. (GILD) vs Unilever plc (UL) Price & Performance

Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.

The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.

Unilever (UL) trades at $62.86, down 0.16% on the day, with a bearish technical signal. The stock shows strong profitability with a net income margin of 18.75% and ROE of 53.32%, though recent quarters have seen EPS misses. Revenue declined to $50.50B in 2025, but cash flow from operations remains robust at $8.35B. News highlights include a planned $65 billion merger with McCormick's food business and strong Q2 2026 volume growth, prompting an upgraded outlook.

The outlook is mixed: valuation ratios like P/E of 20.84 are reasonable, and the merger could drive growth, but consistent earnings misses and a high P/B of 7.49 pose risks. Analyst sentiment is neutral with 51.36% hold ratings. Investors should weigh the transformative deal potential against execution risks and margin pressures in a volatile consumer goods market.